How Will The Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Expand At A CAGR Of 10.1% Through 2029?
Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors
What CAGR And Valuation Are Anticipated For The Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market?
The market size for the vesicular monoamine transporter 2 (vmat2) inhibitor has experienced a surge in recent years. It’s projected to make a leap from $1.13 billion in 2024 to $1.25 billion in 2025, recording a compound annual growth rate (CAGR) of 10.3%. The escalation during the historical period can be linked to the rising occurrences of movement disorders, an increased demand for efficient treatments, growing knowledge about tardive dyskinesia, a swelling aged population, and an increased predilection for oral formulations.
Predicted expansion in the vesicular monoamine transporter 2 (vmat2) inhibitor market is poised to be swift in the coming years. The anticipated growth rate is 10.1% annually, reaching a significant “$1.83 billion by 2029. The surge through the forecasted period is mainly due to the escalating prevalence of neurodegenerative ailments, increasing application of targeted treatments, the rising emphasis on customized medicine, amplified funding in research and development, and the mounting awareness about psychiatric and motor disorders. Key industry trends expected in this period encompass progress in neurological research, enhancements in drug composition, a shift towards targeted and precision medication, evolution of succeeding generation VMAT2 inhibitors, and the incorporation of digital healthcare technologies.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21317&type=smp
What Underlying Factors Are Supporting The Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Growth?
The growth of the vesicular monoamine transporter 2 (VMAT2) inhibitor market is slated to surge due to the rising occurrence of Parkinson’s disease. This progressive neurological disorder impacts movement and is caused by the deterioration of dopamine-producing cells in the brain. The rise in Parkinson’s disease is largely attributed to an aging population, improved diagnostic techniques, exposure to environmental toxins, hereditary factors, and heightened awareness about the disease. VMAT2 inhibitors play a significant role in managing the symptoms of Parkinson’s disease by regulating dopamine release and diminishing tremors and dyskinesia. For example, the Parkinson’s Foundation, a non-profit organization based in the U.S., reported in December 2022 that around 90,000 individuals were diagnosed with Parkinson’s disease in the U.S., a 50% surge from the prior annual estimate of 60,000 diagnoses. Hence, the escalating prevalence of Parkinson’s disease is spurring the growth of the vesicular monoamine transporter 2 (VMAT2) inhibitor market.
What Are The Primary Segmentation Parameters In The Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market?
The vesicular monoamine transporter 2 (vmat2) inhibitor market covered in this report is segmented –
1) By Drugs: Tetrabenazine, Deutetrabenazine, Valbenazine, Other Drugs
2) By Route Of Administration: Oral, Other Administrations
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By Application: Huntington’s Disease, Tardive Dyskinesia, Other Applications
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Tetrabenazine: Huntington’s Disease Treatment, Tardive Dyskinesia Management, Tourette Syndrome Treatment
2) By Deutetrabenazine: Huntington’s Disease Chorea, Tardive Dyskinesia Treatment, Off-Label Movement Disorders
3) By Valbenazine: Tardive Dyskinesia Treatment, Tourette Syndrome Research, Other Hyperkinetic Movement Disorders
4) By Other Drugs: Investigational VMAT2 Inhibitors, Emerging Therapies For Movement Disorders, Off-Label Use In Neurological Conditions
Which Emerging Trends Are Reshaping The Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Landscape?
Companies leading the vesicular monoamine transporter 2 (VMAT2) inhibitors market are concentrating on creating innovative formats like capsules to boost patient adherence, fortify drug stability, and maximize pharmacological performance. In a gelatin or HPMC casing, capsules act as a solid dosage form that aid VMAT2 inhibitors in amplifying medication stability, guaranteeing precise dosage, and heightening patient adherence. For instance, Neurocrine Biosciences Inc., a biopharmaceutical enterprise based in the U.S., unveiled Ingrezza Sprinkle (valbenazine) capsules in July 2024. These capsules are a reformulation of the VMAT2 inhibitor Ingrezza, and are designed to make administration easier for adults suffering from tardive dyskinesia and chorea linked to Huntington’s disease who face challenges swallowing. Ingrezza Sprinkle provides equivalent dosing options as Ingrezza and can either be swallowed as a whole or the content can be scattered onto soft food.
Which Organizations Are At The Forefront Of The Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market?
Major companies operating in the vesicular monoamine transporter 2 (VMAT2) inhibitor market are Thermo Fisher Scientific Inc., Eli Lilly and Company, Merck KGaA, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Otsuka Pharmaceutical, Astellas Pharma, Bausch Health Companies Inc., Avantor Inc., Sun Pharmaceutical Industries Limited, Sumitomo Dainippon Pharma, Dr. Reddy’s Laboratories Ltd., H. Lundbeck A/S, Hikma Pharmaceuticals plc, Lupin Limited, Neurocrine Biosciences Inc., Luye Pharma Group Ltd., Ventegra Inc., Mitsubishi Tanabe Pharma Corporation, Biomol GmbH
Access The Complete Report Here:
Which Region Holds The Greatest Opportunity For Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Expansion?
North America was the largest region in the vesicular monoamine transporter 2 (VMAT2) inhibitor market in 2024. The regions covered in the vesicular monoamine transporter 2 (VMAT2) inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=21317&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
